Market Research Logo

Trigeminal Neuralgia - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Trigeminal Neuralgia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H1 2015’, provides an overview of the Trigeminal Neuralgia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Trigeminal Neuralgia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Trigeminal Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Trigeminal Neuralgia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Trigeminal Neuralgia Overview
Therapeutics Development
Pipeline Products for Trigeminal Neuralgia - Overview
Pipeline Products for Trigeminal Neuralgia - Comparative Analysis
Trigeminal Neuralgia - Therapeutics under Development by Companies
Trigeminal Neuralgia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Trigeminal Neuralgia - Products under Development by Companies
Trigeminal Neuralgia - Companies Involved in Therapeutics Development
Allergan, Inc.
Convergence Pharmaceuticals Ltd.
Merz Pharma GmbH & Co. KgaA
Trigemina, Inc.
Trigeminal Neuralgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(naltrexone hydrochloride+ clonidine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNV-1014802 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trigeminal Neuralgia - Recent Pipeline Updates
Trigeminal Neuralgia - Product Development Milestones
Featured News & Press Releases
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Trigeminal Neuralgia, H1 2015
Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Trigeminal Neuralgia - Pipeline by Allergan, Inc., H1 2015
Trigeminal Neuralgia - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015
Trigeminal Neuralgia - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015
Trigeminal Neuralgia - Pipeline by Trigemina, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Trigeminal Neuralgia Therapeutics - Recent Pipeline Updates, H1 2015
List of Figures
Number of Products under Development for Trigeminal Neuralgia, H1 2015
Number of Products under Development for Trigeminal Neuralgia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report